SOAT1 and mycosis fungoides: On the contrary, our in vitro data previously demonstrated that the Resminostat/Ruxolitinib drug combination affected the activation of AKT in both cell lines, whereas it also inhibited JAK/STAT and MAPK activation in the MF cell line.